GlassScriptPhysician profile
Barry H Lowell
NPI 1780735563
$20,990.78
in general payments reported to CMS, 2019-2025
60 companies · $2,953 in 2025
The $2,953 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,742 · 2020: $2,957 · 2021: $1,901 · 2022: $2,688 · 2023: $3,748 · 2024: $3,002 · 2025: $2,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,061 · Travel and Lodging: $622 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,061.06 |
| Travel and Lodging | $621.87 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,491.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic Vascular, INC. | $1,736.64 | 2020 | |
| Novartis Pharmaceuticals Corporation | $1,412.76 | 2019-2025 | |
| Boston Scientific Corporation | $1,372.51 | 2019-2024 | Watchman Access System, Watchman, Watchman Flx |
| Janssen Pharmaceuticals, INC | $1,281.90 | 2019-2024 | Xarelto |
| Pfizer INC. | $997.42 | 2019-2025 | |
| Abbott Laboratories | $905.25 | 2019-2025 | Xience Skypoint, Diamondback Coronary, Thoratec Heartmate 3 Lvas Implant Kit |
| Sanofi-Aventis U.S. LLC | $886.30 | 2019-2024 | |
| Amgen INC. | $840.27 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $739.10 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $707.54 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $703.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $698.06 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Merck Sharp & Dohme LLC | $635.98 | 2019-2025 | Verquvo, Capvaxive |
| Abiomed | $596.56 | 2019-2025 | Impella |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $476.47 | 2021-2025 | Symplicity G3, Corevalve Evolut R, Ffrangio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $466.16 | 2019-2025 | Lifevest |
| Lilly USA, LLC | $454.62 | 2019-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $443.78 | 2019-2025 | Eliquis, Camzyos |
| Alnylam Pharmaceuticals INC. | $276.46 | 2023-2025 | Onpattro |
| Baxter Healthcare | $259.25 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor, Hillrom - Monarch Airway Clearance System |
| Amarin Pharma, INC. | $228.62 | 2019-2022 | |
| Esperion Therapeutics, INC. | $214.11 | 2020-2024 | Nexletol |
| Philips North America LLC | $156.33 | 2022-2025 | Mcot, (5044) Mcot |
| Lexicon Pharmaceuticals, INC. | $142.35 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $141.96 | 2022-2023 | Arcalyst |
| Lundbeck LLC | $134.19 | 2019-2021 | |
| Shockwave Medical, INC | $131.35 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Irhythm Technologies, INC. | $124.03 | 2019-2023 | Zio Xt Patch |
| Impulse Dynamics (USA) INC. | $113.44 | 2022-2025 | Optimizer, Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $107.53 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $94.86 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Heartflow, INC. | $92.96 | 2023-2025 | Ffrct |
| Cvrx, INC. | $88.21 | 2024-2025 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $87.41 | 2019-2025 | Evkeeza |
| Bridgebio Pharma, INC. | $75.82 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $58.65 | 2021-2022 | |
| Cardiovascular Systems INC. | $57.97 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $53.33 | 2019-2021 | |
| United Therapeutics Corporation | $50.75 | 2023-2025 | Tyvaso, Tyvaso |
| Scpharmaceuticals INC. | $49.05 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $48.01 | 2023-2025 | Opsumit, Opsynvi |
| Chiesi USA, INC. | $44.40 | 2020-2022 | |
| Vivus LLC | $30.00 | 2019-2022 | |
| Acist Medical Systems, INC. | $25.52 | 2023 | |
| Althera Pharmaceuticals LLC | $23.41 | 2022 | |
| Edwards Lifesciences Corporation | $20.85 | 2019 | |
| Atricure, INC. | $20.82 | 2024 | |
| Angiodynamics, INC. | $20.58 | 2023 | Auryon Laser System 100-120 Vac |
| Recor Medical INC | $19.85 | 2025 | Paradise Ultrasound Renal Denervation System |
| Bardy Diagnostics, INC. | $19.05 | 2019-2020 | |
| Cashflow Solutions, LLC | $18.26 | 2025 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Kestra Medical Technology Services, INC. | $16.98 | 2025 | Assure Wcd |
| Exact Sciences Corporation | $16.57 | 2024 | Cologuard Collection Kit |
| Cardiva Medical, INC. | $14.44 | 2024 | Optowire |
| Celonova Biosciences, INC. | $13.99 | 2019 | |
| Allergan, INC. | $13.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.83 | 2025 | Glassia |
| Hikma Pharmaceuticals USA | $12.83 | 2022 | |
| Currax Pharmaceuticals LLC | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Lowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.